These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 24646052

  • 21. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
    Takebayashi K, Sakurai S, Suzuki T, Hori K, Terasawa T, Naruse R, Hara K, Suetsugu M, Tsuchiya T, Aoki H, Hamasaki T, Shuutou H, Inukai T.
    Endocr J; 2014; 61(10):1031-9. PubMed ID: 25185672
    [Abstract] [Full Text] [Related]

  • 22. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C, Tsai M, Liu J, Zhao Z, Schmidt E, Xie J.
    Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
    [Abstract] [Full Text] [Related]

  • 23. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Pratley RE.
    Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685
    [Abstract] [Full Text] [Related]

  • 24. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
    White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S, EXAMINE Investigators.
    Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [Abstract] [Full Text] [Related]

  • 26. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 27. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
    Nakamura Y, Inagaki M, Shimizu T, Fujita K, Inoue M, Gotoh H, Oguchi K, Goto Y.
    Nephron Clin Pract; 2013 Apr; 123(1-2):46-51. PubMed ID: 23774306
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ.
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [Abstract] [Full Text] [Related]

  • 29. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H.
    Life Sci; 2009 Jul 17; 85(3-4):122-6. PubMed ID: 19427871
    [Abstract] [Full Text] [Related]

  • 30. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
    Keating GM.
    Drugs; 2015 May 17; 75(7):777-96. PubMed ID: 25855222
    [Abstract] [Full Text] [Related]

  • 31. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May 27; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract] [Full Text] [Related]

  • 32. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA, Frimpong JO.
    J Am Pharm Assoc (2003); 2013 May 27; 53(4):442-7. PubMed ID: 23892821
    [No Abstract] [Full Text] [Related]

  • 33. A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes.
    Nishimura R, Osonoi T, Koike Y, Miyata K, Shimasaki Y.
    Adv Ther; 2019 Nov 27; 36(11):3096-3109. PubMed ID: 31562608
    [Abstract] [Full Text] [Related]

  • 34. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
    Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T.
    Drug Res (Stuttg); 2016 Jan 27; 66(1):18-22. PubMed ID: 26125284
    [Abstract] [Full Text] [Related]

  • 35. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H, Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial.
    Diabetes Care; 2016 Jan 27; 39(1):139-48. PubMed ID: 26628419
    [Abstract] [Full Text] [Related]

  • 36. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.
    Kaku K.
    Expert Opin Pharmacother; 2015 Jan 27; 16(16):2539-47. PubMed ID: 26523434
    [Abstract] [Full Text] [Related]

  • 37. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
    Kishimoto S, Kinoshita Y, Matsumoto T, Maruhashi T, Kajikawa M, Matsui S, Hashimoto H, Takaeko Y, Kihara Y, Chayama K, Goto C, Mohamad Yusoff F, Nakashima A, Noma K, Higashi Y.
    Am J Hypertens; 2019 Jun 11; 32(7):695-702. PubMed ID: 31045223
    [Abstract] [Full Text] [Related]

  • 38. [Alogliptin].
    Tanabe A, Kaku K.
    Nihon Rinsho; 2011 May 11; 69(5):871-6. PubMed ID: 21595274
    [Abstract] [Full Text] [Related]

  • 39. Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
    Nozue T, Fukui K, Takamura T, Sozu T, Hibi K, Kishi S, Michishita I.
    J Cardiol; 2017 Mar 11; 69(3):518-522. PubMed ID: 27236239
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.